BGM and CGM Market

BGM AND CGM MARKET OVERVIEW

The global BGM and CGM market size was USD 16.73 billion in 2025 and is projected to touch USD 36.91 billion by 2033, exhibiting a CAGR of 10.4% during the forecast period. 

The Blood Glucose Monitoring (BGM) and Continuous Glucose Monitoring (CGM) market is growing significantly due to the increasing number of diabetes cases worldwide and a growing awareness of the importance of proactive glucose management. BGM devices, such as conventional blood glucose meters and test strips, give users an instantaneous snapshot of their glucose status at any point in time. CGM systems, however, use sensors implanted under the skin to monitor glucose levels continuously in real-time, giving trend information and alarms that can assist users and healthcare professionals in making better decisions regarding diabetes management.

The market is also driven by technological innovation resulting in more accurate, convenient, and user-friendly devices. Innovations range from smaller sensors, extended sensor lifespan, smartphone and other digital health platform integration, and the creation of artificial intelligence algorithms to deliver personalized insights and predictive warnings. The expanding use of CGM, in turn, is being fueled by its potential to provide a more complete picture of glucose patterns and enhance glycemic control, which ultimately translates into improved health outcomes for people with diabetes.

COVID-19 IMPACT:  

"BGM and CGM Industry Had a Negative Effect Due to supply chain disruption during COVID-19 Pandemic"

The global COVID-19 pandemic has been unprecedented and staggering, with the BGM and CGM market experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to the market’s growth being significantly accelerated by the pandemic.

The COVID-19 pandemic aided the BGM and CGM market positively through the enhanced demand for remote patient monitoring and the capability of enhancing glycemic control in diabetic patients. Lockdowns and travel restrictions limited in-person visits to healthcare providers, rendering them reliant on remote monitoring technology like CGM, which allowed them to remotely monitor patients' blood glucose levels. The FDA also expanded the pandemic-era approved use of CGM devices in hospitals. Economic uncertainty did not redirect patient spending away from required medical devices like BGM and CGM; instead, the focus on managing underlying health conditions like diabetes, which increased the risk of severe COVID-19, probably drove greater adoption. The pandemic did not impact "cultivation" of BGM and CGM since they are medical devices but highlighted their critical contribution to diabetes care during a health crisis, thus fueling market growth. 

LATEST TREND

"Technological Upgrades, User-Centric Design, and Digital Integration Leading the BGM and CGM Market"

Recent trends in the BGM and CGM space are clearly led by technology advancements, improved user interface, and integration with digital health ecosystems. One of the key trends is the increasing adoption of Continuous Glucose Monitoring (CGM) systems over their traditional Blood Glucose Monitoring (BGM) systems due to their ability to provide real-time glucose data, trend analysis, and alarms, leading to improved glycemic control. Among the major innovations are sensor miniaturization, longer wear durations for sensors, and improved accuracy of both BGM and CGM systems. Strong integration with mobile apps and smart devices for easy data tracking, sharing with medical professionals, and personalized feedback is also given. Development of non-invasive glucose monitoring technology is an area of intense research and development. Moreover, integration of insulin pumps and artificial pancreas systems are in the pipeline, with a vision to facilitate more independent and precise control of diabetes. Interest is also growing in leveraging BGM and CGM information for personalized health and wellness, even outside of diabetes management, in athletes and wellness enthusiasts.

BGM AND CGM MARKET SEGMENTATION

By Type

Based on Type, the global market can be categorized into BGM and CGM

• Blood Glucose Monitoring (BGM): This category encompasses conventional blood glucose meters and test strips. These instruments need a sample of blood, usually from a fingerstick, to estimate blood glucose levels at a single point in time. BGM is still a popular means of glucose monitoring because it has a lower initial investment and has a well-established position in the marketplace.

• Continuous Glucose Monitoring (CGM): This category includes meters that continuously monitor glucose in real-time through a sensor placed beneath the skin. CGM devices offer dynamic glucose information, trends, and alarms for high and low glucose values, giving better insight into patterns of glucose versus BGM. Use of CGM is accelerating because of clinical advantages and convenience.

By Application

Based on application, the global market can be categorized into Household, Hospital, Other

• Household (Homecare): This category entails people with diabetes who employ BGM and CGM devices to monitor their blood glucose levels at home. It is the largest application category, fueled by the escalating rate of diabetes and the increased utilization of home-based diabetes treatment.

• Hospital (and Clinics): This category includes the application of BGM and CGM devices in hospitals for monitoring patients' glucose levels during inpatient treatment, surgery, and in outpatient clinics. Hospitals need precise and accurate glucose monitoring for proper patient management.

• Other: This section could include research applications, diagnostic centers, and perhaps new wellness uses where people without diabetes can utilize CGM for individualized health information.

MARKET DYNAMICS

Market dynamics include driving and restraining factors, opportunities and challenges stating the market conditions.                         

DRIVING FACTORS

"Growing Diabetes Prevalence and Rising Awareness of Glucose Monitoring to Support the Market"

One of the key drivers of the BGM and CGM market growth is the growing global diabetes prevalence and the rising awareness of individuals and medical professionals regarding the need for effective blood glucose control to avoid complications and enhance the quality of life. This makes the use of monitoring devices imperative for diagnosis and continuous management.

"Advances in Technology Causing Convenient and Precise Products to Broaden the Market"

Ongoing R&D in CGM and BGM technologies into more precise, convenient, and user-friendly devices is one factor that fuels growth in the market. This also involves the creation of smaller-sized sensors, more extended wear, wireless capabilities, smartphone compatibility, and creating superior algorithms for interpreting data and pre-empting alerts, improving glucose monitoring into a less demanding and less obtrusive condition.

RESTRAINING FACTOR

"High Price and Low Reimbursement in Some Geographies Potentially to Deter Market Expansion"

One key restraint in the BGM and CGM market is the excessive cost of the devices, more so for CGM systems and their recurring расходные материалы (consumables). Low reimbursement and insurance coverages in certain geographies will limit access by a large majority of the patient population, stifling wider adoption of the market even with its clinical advantages.

OPPORTUNITY

"Integration with Digital Health Ecosystems and Artificial Intelligence to Generate Opportunities"

The increasing trend of combining BGM and CGM data with digital health platforms, such as mobile apps, electronic health records (EHRs), and telehealth services, is a huge opportunity. In addition, the use of artificial intelligence (AI) to interpret glucose data, offer personalized insights, and even automate insulin delivery systems (artificial pancreas) has huge potential to enhance diabetes management and fuel market growth.

CHALLENGE

"Ensuring Data Security and Patient Privacy While Enhancing Connectivity Could Be a Potential Challenge"

As BGM and CGM devices become more interconnected and produce vast amounts of personal health information, having strong data security and patient privacy protection becomes an imperative challenge. Resolution of issues around data breaches, unauthorized access, and ethical use of this sensitive data is crucial to sustaining patient confidence and encouraging the mass adoption of connected glucose monitoring technologies.

BGM AND CGM MARKET REGIONAL INSIGHTS

• 
•  

• North America

North America is an important and mature market for CGM and BGM, with the United States BGM and CGM Market being the leading market with a high diabetes prevalence and a well-developed healthcare infrastructure for the adoption of sophisticated diabetes care technologies. Resilient reimbursement policies and a strong market share of prominent players stimulating innovation also support the region's leadership position, specifically in the adoption of advanced CGM systems and connected digital health solutions for diabetes care.

• Europe

Europe possesses a high BGM and CGM market share, with strong healthcare systems across countries such as Germany, the UK, and France increasingly embracing the clinical value and cost-effectiveness of advanced glucose monitoring. These nations tend to have beneficent reimbursement systems and are experiencing increasing movement towards the adoption of CGMs as healthcare professionals and patients become aware of the benefits of having access to real-time glucose readings for better glycemic control and fewer diabetes-related complications. Having strong national health systems makes it easier for more people to access these technologies.

• Asia

The Asia-Pacific region is the most rapidly expanding market for the BGM and CGM space, spurred by a sharply increasing incidence of diabetes, especially among densely populated countries such as India and China, combined with better access to healthcare and increased expenditure on healthcare. Although BGM continues to dominate because of cost factors in certain geographies, the region is witnessing growing uptake of CGM, particularly in higher-income segments and as awareness of its advantages increases among patients and healthcare providers. The market in this region offers strong long-term growth prospects for BGM and CGM manufacturers.

KEY INDUSTRY PLAYERS

"Industry Leaders Driving the Market with Innovation and Market Growth"

Major business players are driving the BGM and CGM marketplace through innovative business strategies and market growth. Some of these players are leading medical device companies dealing in diabetes care, including Abbott, Dexcom, Medtronic, and Roche. These players are leading the charge in launching technologically sophisticated BGM and CGM systems that are more accurate, user-friendly, and offer connectivity features. They are constantly investing in research and development to develop novel sensors, algorithms, and connected digital platforms for better glucose monitoring and management. In addition, other major competitors such as Senseonics, Ypsomed, Ascensia Diabetes Care, and LifeScan add their own BGM and CGM offerings to the market. They are concentrating on building longer-life sensors, less conspicuous and user-friendly devices, and easy integration with insulin infusion systems and digital health platforms. With further expansion of product portfolios, development of better device features, and strategic entry in new geographies, these lead industry players are fueling the growth and trends in the BGM and CGM market in order to change the lives of people with diabetes.

LIST OF TOP BGM AND CGM COMPANIES

• Abbott (U.S.)
• Dexcom (U.S.)
• Roche (Switzerland)
• Lifescan (U.S.)
• Ascensia (Switzerland)
• Medtronic (U.S.)
• ARKRAY (Japan)
• Sinocare (China)
• I-SENS (South Korea)
• Terumo (Japan)
• B. Braun (Germany)
• Acon (U.S.)
• Yicheng (China)
• Omron (Japan)
• SD Biosensor (Korea)
• 77 Elektronika (Hungary)
• Yuwell (China)
• Osang Healthcare (Korea)
• AgaMatrix (U.S.)
• Senseonics Holdings (U.S.)

KEY INDUSTRY DEVELOPMENT

October 2023: One of the major developments in the BGM and CGM market was a greater emphasis on interoperability and compatibility with other digital health platforms. Some major manufacturers issued partnerships and collaborations to facilitate unproblematic data exchange between their BGM and CGM models and well-known fitness trackers, smartwatches, and electronic health record (EHR) systems. The new initiative was aimed at giving health care providers and users a comprehensive perspective of the health information for more informed decisions in diabetes and customized care approach. The connectivity focus was also a part of a larger global shift towards inter-connected digital solutions for health care.

REPORT COVERAGE   

The report incorporates an extensive SWOT analysis and gives insight into future growth of the BGM and CGM market. The research explores many of the elements contributing to growth in the market, covering an extensive variety of market segments and prospective uses which can affect its growth pattern over the next several years. The report considers both ongoing trends and past turning points, giving a comprehensive view of the parts of the market and the areas where development can be expected.

The BGM and CGM market is growing strongly and consistently as a result of rising global incidence of diabetes, technological development in monitoring, and heightened focus on preventive management of diabetes. In spite of the hurdles like the expense of CGM systems and broader reimbursement requirements, demand for more precise, streamlined, and connected blood glucose monitoring solutions is robust. Major industry players are investing heavily in sensor technology, data analytics, and linking with digital health platforms, which are making BGM and CGM devices more useful and desirable. With the emphasis on customized and telemedicine healthcare solutions growing stronger day by day, the BGM and CGM market is likely to sustain its strong growth pattern, driven by continuing technological innovation and widening applications in diabetes control and possibly outside of this space.